Skip to main content
Top
Published in: Rheumatology International 3/2010

01-01-2010 | Original Article

The relation between osteoporosis and vitamin D levels and disease activity in ankylosing spondylitis

Authors: Bedriye Mermerci Başkan, Yasemin Pekin Doğan, Filiz Sivas, Hatice Bodur, Kürşat Özoran

Published in: Rheumatology International | Issue 3/2010

Login to get access

Abstract

In this study, the relation between osteoporosis and vitamin D and the disease activity in patients with ankylosing spondylitis (AS) was investigated. A hundred patients with AS and 58 healthy individuals were included in the study. In addition to the routine blood and urine tests, serum 25-(OH)D3, parathormone (PTH), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), total calcium, ionized calcium, and phosphorous levels of all participants were also measured. Bone mineral density (BMD) measurements were performed at the anterior–posterior and lateral lumbar and femur regions. Anterior–posterior and lateral thoracic and lumbosacral radiography was performed on all participants. The disease activity was evaluated by Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), functional status by Bath Ankylosing Spondylitis Functional Index (BASFI), and mobility by Bath Ankylosing Spondylitis Metrology Index (BASMI). In the patient group, BMD values obtained from the lateral lumbar and femur regions and serum vitamin D levels were lower than the control group. A negative relation was determined between the lateral lumbar BMD values and ESR, CRP, and BASDAI scores of patients with AS. The ESR, CRP levels, and BASMI scores of the AS patients with osteoporosis were significantly higher, when compared to patients without osteoporosis. The negative correlation between serum 25-(OH)D3 level and ESR, CRP levels did not reach a statistically significant level in patients with AS; the positive correlation between PTH levels and ESR, and the negative correlation between CRP and BASDAI also did not reach a statistically significant level. Vitamin D deficiency in AS may indirectly lead to osteoporosis by causing an increase in the inflammatory activity. The present authors believe that it would be beneficial to monitorize vitamin D levels together with BMD measurements in order to determine the patients under osteoporosis risk.
Literature
1.
go back to reference Van Der Linden S, Van Der Hejide D, Braun J (2005) Ankylosing spondylitis. In: Harris ED, Budd RC, Frestein GS et al (eds) Kelley’s textbook of rheumatology. Elsevier Saunders, Philadelphia, PA, pp 1125–1141 Van Der Linden S, Van Der Hejide D, Braun J (2005) Ankylosing spondylitis. In: Harris ED, Budd RC, Frestein GS et al (eds) Kelley’s textbook of rheumatology. Elsevier Saunders,  Philadelphia, PA, pp 1125–1141
2.
go back to reference Will R, Palmer R, Bhalla AK et al (1989) Osteoporosis in early ankylosing spondylitis: a primary pathological event? Lancet 2(8678–8679):1483–1485CrossRefPubMed Will R, Palmer R, Bhalla AK et al (1989) Osteoporosis in early ankylosing spondylitis: a primary pathological event? Lancet 2(8678–8679):1483–1485CrossRefPubMed
3.
go back to reference Gratacos J, Collado A, Pons F et al (1999) Significant loss of bone mass in patients with early, active ankylosing spondylitis: a followup study. Arthritis Rheum 42(11):2319–2324CrossRefPubMed Gratacos J, Collado A, Pons F et al (1999) Significant loss of bone mass in patients with early, active ankylosing spondylitis: a followup study. Arthritis Rheum 42(11):2319–2324CrossRefPubMed
4.
go back to reference Lange U, Teichmann J, Strunk J et al (2005) Association of 1.25 vitamin D3 deficiency, disease activity and low bone mass in ankylosing spondylitis. Osteoporos Int 16(12):1999–2004CrossRefPubMed Lange U, Teichmann J, Strunk J et al (2005) Association of 1.25 vitamin D3 deficiency, disease activity and low bone mass in ankylosing spondylitis. Osteoporos Int 16(12):1999–2004CrossRefPubMed
5.
go back to reference Lange U, Jung O, Teichmann J et al (2001) Relationship between disease activity and serum levels of vitamin D metabolites and parathyroid hormone in ankylosing spondylitis. Osteoporos Int 12(12):1031–1035CrossRefPubMed Lange U, Jung O, Teichmann J et al (2001) Relationship between disease activity and serum levels of vitamin D metabolites and parathyroid hormone in ankylosing spondylitis. Osteoporos Int 12(12):1031–1035CrossRefPubMed
7.
go back to reference Pacifici R (1995) Cytokines and osteoclast activity. Calcif Tissue Int 56(Suppl 1):S27–S28PubMed Pacifici R (1995) Cytokines and osteoclast activity. Calcif Tissue Int 56(Suppl 1):S27–S28PubMed
8.
go back to reference Nguyen L, Dewhirst FE, Hauschka PV et al (1991) Interleukin-1 beta stimulates bone resorption and inhibits bone formation in vivo. Lymphokine Cytokine Res 10(1–2):15–21PubMed Nguyen L, Dewhirst FE, Hauschka PV et al (1991) Interleukin-1 beta stimulates bone resorption and inhibits bone formation in vivo. Lymphokine Cytokine Res 10(1–2):15–21PubMed
9.
go back to reference Fujita T, Matsui T, Nakao Y et al (1990) Cytokines and osteoporosis. Ann N Y Acad Sci 587:371–375PubMed Fujita T, Matsui T, Nakao Y et al (1990) Cytokines and osteoporosis. Ann N Y Acad Sci 587:371–375PubMed
10.
go back to reference Baier R, Grauer A, Lazaretti-Castro M et al (1994) Differential effects of 1, 25-dihydroxyvitamin D3 on cell proliferation and calcitonin gene expression. Endocrinology 135(5):2006–2011CrossRefPubMed Baier R, Grauer A, Lazaretti-Castro M et al (1994) Differential effects of 1, 25-dihydroxyvitamin D3 on cell proliferation and calcitonin gene expression. Endocrinology 135(5):2006–2011CrossRefPubMed
11.
go back to reference Muller K, Bendtzen K (1996) 1,25-Dihydroxyvitamin D3 as a natural regulator of human immune functions. J Investig Dermatol Symp Proc 1(1):68–71PubMed Muller K, Bendtzen K (1996) 1,25-Dihydroxyvitamin D3 as a natural regulator of human immune functions. J Investig Dermatol Symp Proc 1(1):68–71PubMed
13.
go back to reference Bouillon R, Okamura WH, Norman AW (1995) Structure-function relationships in the vitamin D endocrine system. Endocr Rev 16(2):200–257PubMed Bouillon R, Okamura WH, Norman AW (1995) Structure-function relationships in the vitamin D endocrine system. Endocr Rev 16(2):200–257PubMed
14.
go back to reference Cantorna MT, Mahon BD (2005) D-hormone and the immune system. J Rheumatol Suppl 76:11–20PubMed Cantorna MT, Mahon BD (2005) D-hormone and the immune system. J Rheumatol Suppl 76:11–20PubMed
15.
go back to reference Deluca HF, Cantorna MT (2001) Vitamin D: its role and uses in immunology. Faseb J 15(14):2579–2585CrossRefPubMed Deluca HF, Cantorna MT (2001) Vitamin D: its role and uses in immunology. Faseb J 15(14):2579–2585CrossRefPubMed
16.
go back to reference van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27(4):361–368CrossRefPubMed van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27(4):361–368CrossRefPubMed
17.
go back to reference Garrett S, Jenkinson T, Kennedy LG et al (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21(12):2286–2291PubMed Garrett S, Jenkinson T, Kennedy LG et al (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21(12):2286–2291PubMed
18.
go back to reference Calin A, Garrett S, Whitelock H et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21(12):2281–2285PubMed Calin A, Garrett S, Whitelock H et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21(12):2281–2285PubMed
19.
go back to reference Yanik B, Gursel YK, Kutlay S et al (2005) Adaptation of the Bath Ankylosing Spondylitis Functional Index to the Turkish population, its reliability and validity: functional assessment in AS. Clin Rheumatol 24(1):41–47CrossRefPubMed Yanik B, Gursel YK, Kutlay S et al (2005) Adaptation of the Bath Ankylosing Spondylitis Functional Index to the Turkish population, its reliability and validity: functional assessment in AS. Clin Rheumatol 24(1):41–47CrossRefPubMed
20.
go back to reference Ay S, Kutlay Ş, Kurtaiş Y (2004) Ankilozan Spondilitli Hastalarda Bath Ankilozan Spondilit Hastalık Aktivite İndeksinin (BASHAİ) Türkçe Versiyonunun Geçerlilik Ve Güvenirlik Çalışması. Romatizma (Acta Rheumatol Turcica) 19(3):139–146 Ay S, Kutlay Ş, Kurtaiş Y (2004) Ankilozan Spondilitli Hastalarda Bath Ankilozan Spondilit Hastalık Aktivite İndeksinin (BASHAİ) Türkçe Versiyonunun Geçerlilik Ve Güvenirlik Çalışması. Romatizma (Acta Rheumatol Turcica) 19(3):139–146
21.
go back to reference Jenkinson TR, Mallorie PA, Whitelock HC et al (1994) Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 21(9):1694–1698PubMed Jenkinson TR, Mallorie PA, Whitelock HC et al (1994) Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 21(9):1694–1698PubMed
22.
go back to reference Melton LJIII, Lane AW, Cooper C et al (1993) Prevalence and incidence of vertebral deformities. Osteoporos Int 3(3):113–119CrossRefPubMed Melton LJIII, Lane AW, Cooper C et al (1993) Prevalence and incidence of vertebral deformities. Osteoporos Int 3(3):113–119CrossRefPubMed
23.
go back to reference Ozoran K, Paker N, Basgoze O et al (1989) Calcitonin and calcium combined therapy in osteoporosis: effects on vertebra trabecular bone density. J Int Med Res 17(4):395–400PubMed Ozoran K, Paker N, Basgoze O et al (1989) Calcitonin and calcium combined therapy in osteoporosis: effects on vertebra trabecular bone density. J Int Med Res 17(4):395–400PubMed
24.
go back to reference El Maghraoui A, Borderie D, Cherruau B et al (1999) Osteoporosis, body composition, and bone turnover in ankylosing spondylitis. J Rheumatol 26(10):2205–2209PubMed El Maghraoui A, Borderie D, Cherruau B et al (1999) Osteoporosis, body composition, and bone turnover in ankylosing spondylitis. J Rheumatol 26(10):2205–2209PubMed
25.
go back to reference Ralston SH, Urquhart GD, Brzeski M et al (1990) Prevalence of vertebral compression fractures due to osteoporosis in ankylosing spondylitis. BMJ 300(6724):563–565CrossRefPubMed Ralston SH, Urquhart GD, Brzeski M et al (1990) Prevalence of vertebral compression fractures due to osteoporosis in ankylosing spondylitis. BMJ 300(6724):563–565CrossRefPubMed
26.
go back to reference Mullaji AB, Upadhyay SS, Ho EK (1994) Bone mineral density in ankylosing spondylitis DEXA comparison of control subjects with mild and advanced cases. J Bone Joint Surg Br 76(4):660–665PubMed Mullaji AB, Upadhyay SS, Ho EK (1994) Bone mineral density in ankylosing spondylitis DEXA comparison of control subjects with mild and advanced cases. J Bone Joint Surg Br 76(4):660–665PubMed
27.
go back to reference Lange U, Kluge A, Strunk J et al (2005) Ankylosing spondylitis and bone mineral density—what is the ideal tool for measurement? Rheumatol Int 26(2):115–120CrossRefPubMed Lange U, Kluge A, Strunk J et al (2005) Ankylosing spondylitis and bone mineral density—what is the ideal tool for measurement? Rheumatol Int 26(2):115–120CrossRefPubMed
28.
go back to reference Hanson CA, Shagrin JW, Duncan H (1971) Vertebral osteoporosis in ankylosing spondylitis. Clin Orthop Relat Res 74:59–64CrossRefPubMed Hanson CA, Shagrin JW, Duncan H (1971) Vertebral osteoporosis in ankylosing spondylitis. Clin Orthop Relat Res 74:59–64CrossRefPubMed
29.
go back to reference Cooper C, Carbone L, Michet CJ et al (1994) Fracture risk in patients with ankylosing spondylitis: a population based study. J Rheumatol 21(10):1877–1882PubMed Cooper C, Carbone L, Michet CJ et al (1994) Fracture risk in patients with ankylosing spondylitis: a population based study. J Rheumatol 21(10):1877–1882PubMed
30.
go back to reference Donnelly S, Doyle DV, Denton A et al (1994) Bone mineral density and vertebral compression fracture rates in ankylosing spondylitis. Ann Rheum Dis 53(2):117–121CrossRefPubMed Donnelly S, Doyle DV, Denton A et al (1994) Bone mineral density and vertebral compression fracture rates in ankylosing spondylitis. Ann Rheum Dis 53(2):117–121CrossRefPubMed
31.
go back to reference Gratacos J, Collado A, Filella X et al (1994) Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 33(10):927–931CrossRefPubMed Gratacos J, Collado A, Filella X et al (1994) Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 33(10):927–931CrossRefPubMed
32.
33.
go back to reference Meirelles ES, Borelli A, Camargo OP (1999) Influence of disease activity and chronicity on ankylosing spondylitis bone mass loss. Clin Rheumatol 18(5):364–368CrossRefPubMed Meirelles ES, Borelli A, Camargo OP (1999) Influence of disease activity and chronicity on ankylosing spondylitis bone mass loss. Clin Rheumatol 18(5):364–368CrossRefPubMed
34.
go back to reference Franck H, Meurer T, Hofbauer LC (2004) Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis. J Rheumatol 31(11):2236–2241PubMed Franck H, Meurer T, Hofbauer LC (2004) Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis. J Rheumatol 31(11):2236–2241PubMed
35.
go back to reference Saino H, Matsuyama T, Takada J et al (1997) Long-term treatment of indomethacin reduces vertebral bone mass and strength in ovariectomized rats. J Bone Miner Res 12(11):1844–1850CrossRefPubMed Saino H, Matsuyama T, Takada J et al (1997) Long-term treatment of indomethacin reduces vertebral bone mass and strength in ovariectomized rats. J Bone Miner Res 12(11):1844–1850CrossRefPubMed
36.
go back to reference Jiang Y, Zhao J, Genant HK et al (1998) Bone mineral density and biomechanical properties of spine and femur of ovariectomized rats treated with naproxen. Bone 22(5):509–514CrossRefPubMed Jiang Y, Zhao J, Genant HK et al (1998) Bone mineral density and biomechanical properties of spine and femur of ovariectomized rats treated with naproxen. Bone 22(5):509–514CrossRefPubMed
37.
go back to reference Devogelaer JP, Maldague B, Malghem J, Nagant de Deuxchaisnes C (1992) Appendicular and vertebral bone mass in ankylosing spondylitis. A comparison of plain radiographs with single- and dual-photon absorptiometry and with quantitative computed tomography. Arthritis Rheum 35(9):1062–1067CrossRefPubMed Devogelaer JP, Maldague B, Malghem J, Nagant de Deuxchaisnes C (1992) Appendicular and vertebral bone mass in ankylosing spondylitis. A comparison of plain radiographs with single- and dual-photon absorptiometry and with quantitative computed tomography. Arthritis Rheum 35(9):1062–1067CrossRefPubMed
38.
go back to reference Reid DM, Nicoll JJ, Kennedy NS et al (1986) Bone mass in ankylosing spondylitis. J Rheumatol 13(5):932–935PubMed Reid DM, Nicoll JJ, Kennedy NS et al (1986) Bone mass in ankylosing spondylitis. J Rheumatol 13(5):932–935PubMed
39.
go back to reference Masud T, Langley S, Wiltshire P et al (1993) Effect of spinal osteophytosis on bone mineral density measurements in vertebral osteoporosis. BMJ 307(6897):172–173CrossRefPubMed Masud T, Langley S, Wiltshire P et al (1993) Effect of spinal osteophytosis on bone mineral density measurements in vertebral osteoporosis. BMJ 307(6897):172–173CrossRefPubMed
40.
go back to reference Bronson WD, Walker SE, Hillman LS et al (1998) Bone mineral density and biochemical markers of bone metabolism in ankylosing spondylitis. J Rheumatol 25(5):929–935PubMed Bronson WD, Walker SE, Hillman LS et al (1998) Bone mineral density and biochemical markers of bone metabolism in ankylosing spondylitis. J Rheumatol 25(5):929–935PubMed
41.
go back to reference Gilgil E, Kacar C, Tuncer T et al (2005) The association of syndesmophytes with vertebral bone mineral density in patients with ankylosing spondylitis. J Rheumatol 32(2):292–294PubMed Gilgil E, Kacar C, Tuncer T et al (2005) The association of syndesmophytes with vertebral bone mineral density in patients with ankylosing spondylitis. J Rheumatol 32(2):292–294PubMed
42.
go back to reference Bessant R, Keat A (2002) How should clinicians manage osteoporosis in ankylosing spondylitis? J Rheumatol 29(7):1511–1519PubMed Bessant R, Keat A (2002) How should clinicians manage osteoporosis in ankylosing spondylitis? J Rheumatol 29(7):1511–1519PubMed
43.
go back to reference Selby P (2008) Rickets and osteomalacia. In: Hochberg MC (ed) Rheumatology. Mosby Elsevier, Amsterdam, pp 1977–1987 Selby P (2008) Rickets and osteomalacia. In: Hochberg MC (ed) Rheumatology. Mosby Elsevier, Amsterdam, pp 1977–1987
Metadata
Title
The relation between osteoporosis and vitamin D levels and disease activity in ankylosing spondylitis
Authors
Bedriye Mermerci Başkan
Yasemin Pekin Doğan
Filiz Sivas
Hatice Bodur
Kürşat Özoran
Publication date
01-01-2010
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 3/2010
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-009-0975-7

Other articles of this Issue 3/2010

Rheumatology International 3/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.